An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Abstract Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. Methods EGFR-TKI treatment-naïve patients with EGFR mutat...

Full description

Bibliographic Details
Main Authors: Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Afatinib
NSCLC
EGFR
Uncommon mutations
Brain metastases
Real world
Online Access:https://doi.org/10.1186/s12885-021-08445-9

Internet

https://doi.org/10.1186/s12885-021-08445-9

Similar Items